levofolinic acid 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 4384 | 80433-71-2 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A folate analog consisting of the pharmacologically active isomer of LEUCOVORIN.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 30 | mg | O |
| 30 | mg | P |
| 30 | mg | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 11.43 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| Vd (Volume of distribution) | 0.27 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 4.10 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 1.10 hours | Lombardo F, Berellini G, Obach RS |
| S (Water solubility) | 100 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Bocci G, Oprea TI, Benet LZ |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| March 7, 2008 | FDA | SPECTRUM PHARMS | |
| Sept. 21, 2018 | PMDA | Pfizer Japan Inc. |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Neutrophil count decreased | 251.82 | 29.87 | 115 | 5505 | 56291 | 63427111 |
| Dermatitis acneiform | 240.30 | 29.87 | 61 | 5559 | 4935 | 63478467 |
| Paronychia | 191.01 | 29.87 | 52 | 5568 | 5513 | 63477889 |
| Neutropenia | 138.02 | 29.87 | 118 | 5502 | 174887 | 63308515 |
| Decreased appetite | 128.29 | 29.87 | 133 | 5487 | 250919 | 63232483 |
| Peripheral sensory neuropathy | 116.83 | 29.87 | 38 | 5582 | 7413 | 63475989 |
| Stomatitis | 98.10 | 29.87 | 88 | 5532 | 138637 | 63344765 |
| Hyperammonaemia | 91.51 | 29.87 | 29 | 5591 | 5203 | 63478199 |
| Diarrhoea | 79.10 | 29.87 | 186 | 5434 | 715180 | 62768222 |
| Mucosal inflammation | 73.79 | 29.87 | 48 | 5572 | 46880 | 63436522 |
| Neuropathy peripheral | 72.29 | 29.87 | 68 | 5552 | 113599 | 63369803 |
| Large intestine perforation | 63.44 | 29.87 | 25 | 5595 | 8457 | 63474945 |
| Drug ineffective | 63.14 | 29.87 | 9 | 5611 | 1044756 | 62438646 |
| Febrile neutropenia | 62.51 | 29.87 | 64 | 5556 | 118385 | 63365017 |
| Disease progression | 62.40 | 29.87 | 65 | 5555 | 122693 | 63360709 |
| Gastrointestinal perforation | 59.60 | 29.87 | 19 | 5601 | 3472 | 63479930 |
| Myelosuppression | 54.65 | 29.87 | 31 | 5589 | 23672 | 63459730 |
| Nausea | 53.58 | 29.87 | 181 | 5439 | 854290 | 62629112 |
| White blood cell count decreased | 52.39 | 29.87 | 63 | 5557 | 139041 | 63344361 |
| Diarrhoea haemorrhagic | 51.74 | 29.87 | 22 | 5598 | 9020 | 63474382 |
| Hypertransaminasaemia | 51.26 | 29.87 | 20 | 5600 | 6589 | 63476813 |
| Hypomagnesaemia | 49.13 | 29.87 | 31 | 5589 | 28706 | 63454696 |
| Extrasystoles | 48.62 | 29.87 | 18 | 5602 | 5142 | 63478260 |
| Dysentery | 47.49 | 29.87 | 12 | 5608 | 949 | 63482453 |
| Thrombocytopenia | 46.66 | 29.87 | 62 | 5558 | 151095 | 63332307 |
| Bone marrow failure | 46.11 | 29.87 | 30 | 5590 | 29260 | 63454142 |
| Posterior reversible encephalopathy syndrome | 43.56 | 29.87 | 24 | 5596 | 17321 | 63466081 |
| Hypertensive crisis | 43.56 | 29.87 | 23 | 5597 | 15263 | 63468139 |
| Anaemia | 43.26 | 29.87 | 86 | 5534 | 293344 | 63190058 |
| Palmar-plantar erythrodysaesthesia syndrome | 39.77 | 29.87 | 25 | 5595 | 22990 | 63460412 |
| Interstitial lung disease | 37.33 | 29.87 | 36 | 5584 | 61872 | 63421530 |
| Paraesthesia | 36.11 | 29.87 | 56 | 5564 | 156910 | 63326492 |
| Dry skin | 36.05 | 29.87 | 34 | 5586 | 56853 | 63426549 |
| Cholangitis | 33.38 | 29.87 | 14 | 5606 | 5547 | 63477855 |
| Cholinergic syndrome | 33.35 | 29.87 | 8 | 5612 | 510 | 63482892 |
| Metastases to peritoneum | 32.40 | 29.87 | 12 | 5608 | 3430 | 63479972 |
| Colon cancer | 31.40 | 29.87 | 16 | 5604 | 9862 | 63473540 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Dermatitis acneiform | 450.04 | 27.65 | 131 | 8808 | 6058 | 34941934 |
| Paronychia | 385.31 | 27.65 | 102 | 8837 | 3303 | 34944689 |
| Interstitial lung disease | 300.32 | 27.65 | 194 | 8745 | 65088 | 34882904 |
| Neutrophil count decreased | 245.05 | 27.65 | 156 | 8783 | 50948 | 34897044 |
| Peripheral sensory neuropathy | 240.44 | 27.65 | 83 | 8856 | 6677 | 34941315 |
| Stomatitis | 206.75 | 27.65 | 131 | 8808 | 42383 | 34905609 |
| Neuropathy peripheral | 179.01 | 27.65 | 157 | 8782 | 83106 | 34864886 |
| Decreased appetite | 162.97 | 27.65 | 206 | 8733 | 166186 | 34781806 |
| Neutropenia | 136.10 | 27.65 | 183 | 8756 | 156595 | 34791397 |
| Hypomagnesaemia | 133.50 | 27.65 | 78 | 8861 | 21773 | 34926219 |
| Skin disorder | 114.72 | 27.65 | 60 | 8879 | 13495 | 34934497 |
| Hyperammonaemia | 106.10 | 27.65 | 45 | 8894 | 6322 | 34941670 |
| Diarrhoea | 100.33 | 27.65 | 270 | 8669 | 389642 | 34558350 |
| Gastrointestinal perforation | 80.34 | 27.65 | 32 | 8907 | 3831 | 34944161 |
| Palmar-plantar erythrodysaesthesia syndrome | 69.86 | 27.65 | 47 | 8892 | 16748 | 34931244 |
| Nausea | 68.49 | 27.65 | 216 | 8723 | 339692 | 34608300 |
| Drug ineffective | 65.69 | 27.65 | 18 | 8921 | 456733 | 34491259 |
| White blood cell count decreased | 64.35 | 27.65 | 99 | 8840 | 95346 | 34852646 |
| Leukopenia | 63.09 | 27.65 | 79 | 8860 | 62777 | 34885215 |
| Dry skin | 63.06 | 27.65 | 57 | 8882 | 31230 | 34916762 |
| Tumour perforation | 57.70 | 27.65 | 14 | 8925 | 315 | 34947677 |
| Dysgeusia | 54.82 | 27.65 | 49 | 8890 | 26448 | 34921544 |
| Hypersensitivity | 53.87 | 27.65 | 72 | 8867 | 60963 | 34887029 |
| Disease progression | 52.70 | 27.65 | 97 | 8842 | 107980 | 34840012 |
| Febrile neutropenia | 51.29 | 27.65 | 110 | 8829 | 136739 | 34811253 |
| Thrombocytopenia | 50.09 | 27.65 | 118 | 8821 | 156129 | 34791863 |
| Sciatic nerve palsy | 50.03 | 27.65 | 9 | 8930 | 41 | 34947951 |
| Transient aphasia | 45.14 | 27.65 | 12 | 8927 | 393 | 34947599 |
| Bone marrow failure | 39.75 | 27.65 | 43 | 8896 | 29210 | 34918782 |
| Hypertransaminasaemia | 39.54 | 27.65 | 22 | 8917 | 5584 | 34942408 |
| Myelosuppression | 38.60 | 27.65 | 35 | 8904 | 19230 | 34928762 |
| Intestinal ischaemia | 37.74 | 27.65 | 24 | 8915 | 7770 | 34940222 |
| Toxicity to various agents | 37.16 | 27.65 | 4 | 8935 | 200358 | 34747634 |
| Malaise | 37.13 | 27.65 | 118 | 8821 | 185707 | 34762285 |
| Disseminated intravascular coagulation | 36.76 | 27.65 | 36 | 8903 | 21780 | 34926212 |
| Erythema | 36.29 | 27.65 | 74 | 8865 | 88706 | 34859286 |
| Small intestinal perforation | 35.02 | 27.65 | 15 | 8924 | 2156 | 34945836 |
| Colony stimulating factor therapy | 33.40 | 27.65 | 8 | 8931 | 170 | 34947822 |
| Cholinergic syndrome | 32.15 | 27.65 | 10 | 8929 | 577 | 34947415 |
| Hypertension | 31.30 | 27.65 | 91 | 8848 | 136352 | 34811640 |
| Duodenal stenosis | 30.67 | 27.65 | 8 | 8931 | 243 | 34947749 |
| Malignant ascites | 30.35 | 27.65 | 9 | 8930 | 441 | 34947551 |
| Pulmonary artery thrombosis | 29.76 | 27.65 | 10 | 8929 | 738 | 34947254 |
| Peritonitis | 29.44 | 27.65 | 28 | 8911 | 16337 | 34931655 |
| Headache | 28.54 | 27.65 | 8 | 8931 | 200627 | 34747365 |
| Fixed eruption | 28.26 | 27.65 | 12 | 8927 | 1688 | 34946304 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Dermatitis acneiform | 643.51 | 25.19 | 178 | 14114 | 9815 | 79720281 |
| Paronychia | 511.48 | 25.19 | 141 | 14151 | 7667 | 79722429 |
| Neutrophil count decreased | 459.54 | 25.19 | 256 | 14036 | 93703 | 79636393 |
| Interstitial lung disease | 324.75 | 25.19 | 219 | 14073 | 112381 | 79617715 |
| Peripheral sensory neuropathy | 316.48 | 25.19 | 110 | 14182 | 12923 | 79717173 |
| Neutropenia | 289.17 | 25.19 | 304 | 13988 | 287406 | 79442690 |
| Decreased appetite | 280.58 | 25.19 | 325 | 13967 | 342093 | 79388003 |
| Neuropathy peripheral | 260.74 | 25.19 | 210 | 14082 | 141095 | 79589001 |
| Stomatitis | 249.59 | 25.19 | 208 | 14084 | 146549 | 79583547 |
| Hyperammonaemia | 185.02 | 25.19 | 71 | 14221 | 11022 | 79719074 |
| Diarrhoea | 177.08 | 25.19 | 445 | 13847 | 880044 | 78850052 |
| Hypomagnesaemia | 153.83 | 25.19 | 99 | 14193 | 46812 | 79683284 |
| Skin disorder | 127.26 | 25.19 | 78 | 14214 | 33865 | 79696231 |
| White blood cell count decreased | 117.11 | 25.19 | 156 | 14136 | 188132 | 79541964 |
| Gastrointestinal perforation | 115.80 | 25.19 | 43 | 14249 | 6094 | 79724002 |
| Drug ineffective | 112.54 | 25.19 | 28 | 14264 | 1080885 | 78649211 |
| Febrile neutropenia | 112.11 | 25.19 | 170 | 14122 | 230829 | 79499267 |
| Thrombocytopenia | 109.15 | 25.19 | 181 | 14111 | 265078 | 79465018 |
| Disease progression | 104.42 | 25.19 | 146 | 14146 | 184216 | 79545880 |
| Palmar-plantar erythrodysaesthesia syndrome | 99.01 | 25.19 | 66 | 14226 | 33068 | 79697028 |
| Nausea | 93.69 | 25.19 | 378 | 13914 | 956818 | 78773278 |
| Bone marrow failure | 87.83 | 25.19 | 73 | 14219 | 51034 | 79679062 |
| Leukopenia | 87.34 | 25.19 | 106 | 14186 | 116407 | 79613689 |
| Hypertransaminasaemia | 85.28 | 25.19 | 42 | 14250 | 11882 | 79718214 |
| Myelosuppression | 85.16 | 25.19 | 65 | 14227 | 40231 | 79689865 |
| Dry skin | 82.89 | 25.19 | 80 | 14212 | 67915 | 79662181 |
| Dysgeusia | 76.81 | 25.19 | 71 | 14221 | 57106 | 79672990 |
| Tumour perforation | 69.79 | 25.19 | 16 | 14276 | 405 | 79729691 |
| Cholinergic syndrome | 63.68 | 25.19 | 18 | 14274 | 1069 | 79729027 |
| Mucosal inflammation | 61.95 | 25.19 | 72 | 14220 | 75508 | 79654588 |
| Hypertensive crisis | 61.14 | 25.19 | 41 | 14251 | 20729 | 79709367 |
| Large intestine perforation | 58.50 | 25.19 | 35 | 14257 | 14532 | 79715564 |
| Dysentery | 57.49 | 25.19 | 17 | 14275 | 1185 | 79728911 |
| Disseminated intravascular coagulation | 57.05 | 25.19 | 49 | 14243 | 35793 | 79694303 |
| Headache | 57.04 | 25.19 | 23 | 14269 | 653749 | 79076347 |
| Paraesthesia | 56.53 | 25.19 | 108 | 14184 | 176215 | 79553881 |
| Arthralgia | 55.20 | 25.19 | 17 | 14275 | 571786 | 79158310 |
| Colon cancer | 53.45 | 25.19 | 33 | 14259 | 14490 | 79715606 |
| Metastases to liver | 51.89 | 25.19 | 42 | 14250 | 28272 | 79701824 |
| Sciatic nerve palsy | 48.35 | 25.19 | 9 | 14283 | 77 | 79730019 |
| Toxicity to various agents | 47.56 | 25.19 | 9 | 14283 | 421531 | 79308565 |
| Transient aphasia | 47.35 | 25.19 | 12 | 14280 | 468 | 79729628 |
| Hypertension | 46.91 | 25.19 | 148 | 14144 | 330844 | 79399252 |
| Proteinuria | 46.84 | 25.19 | 42 | 14250 | 32460 | 79697636 |
| Platelet count decreased | 45.75 | 25.19 | 105 | 14187 | 194559 | 79535537 |
| Metastases to peritoneum | 45.59 | 25.19 | 20 | 14272 | 4352 | 79725744 |
| Pain | 45.29 | 25.19 | 36 | 14256 | 703766 | 79026330 |
| Cholangitis | 44.42 | 25.19 | 28 | 14264 | 12748 | 79717348 |
| Malaise | 43.30 | 25.19 | 188 | 14104 | 489681 | 79240415 |
| Pulmonary artery thrombosis | 42.64 | 25.19 | 14 | 14278 | 1378 | 79728718 |
| Peritonitis | 41.93 | 25.19 | 37 | 14255 | 27999 | 79702097 |
| Small intestinal perforation | 40.71 | 25.19 | 17 | 14275 | 3280 | 79726816 |
| Hyperthermia | 40.10 | 25.19 | 30 | 14262 | 18007 | 79712089 |
| Malignant neoplasm progression | 39.57 | 25.19 | 80 | 14212 | 135910 | 79594186 |
| Metastases to lung | 37.70 | 25.19 | 29 | 14263 | 18134 | 79711962 |
| Pain in extremity | 36.67 | 25.19 | 10 | 14282 | 364528 | 79365568 |
| Malignant ascites | 36.56 | 25.19 | 12 | 14280 | 1180 | 79728916 |
| Erythema | 36.45 | 25.19 | 105 | 14187 | 223185 | 79506911 |
| Ileus | 36.06 | 25.19 | 33 | 14259 | 26178 | 79703918 |
| Pyrexia | 36.03 | 25.19 | 226 | 14066 | 678483 | 79051613 |
| Intestinal ischaemia | 33.88 | 25.19 | 24 | 14268 | 13246 | 79716850 |
| Colony stimulating factor therapy | 32.16 | 25.19 | 9 | 14283 | 515 | 79729581 |
| Nasopharyngitis | 31.84 | 25.19 | 4 | 14288 | 253877 | 79476219 |
| Anaphylactic shock | 30.67 | 25.19 | 35 | 14257 | 35961 | 79694135 |
| Extrasystoles | 30.24 | 25.19 | 18 | 14274 | 7401 | 79722695 |
| Hyperbilirubinaemia | 30.14 | 25.19 | 29 | 14263 | 24489 | 79705607 |
| Anaemia | 29.30 | 25.19 | 157 | 14135 | 444858 | 79285238 |
| Fall | 28.81 | 25.19 | 27 | 14265 | 487602 | 79242494 |
| Duodenal stenosis | 28.55 | 25.19 | 9 | 14283 | 778 | 79729318 |
| Altered state of consciousness | 28.23 | 25.19 | 37 | 14255 | 43785 | 79686311 |
| Necrotising fasciitis | 28.16 | 25.19 | 16 | 14276 | 6034 | 79724062 |
| Vomiting | 27.75 | 25.19 | 209 | 14083 | 665619 | 79064477 |
| Tumour necrosis | 27.45 | 25.19 | 11 | 14281 | 1911 | 79728185 |
| Drug intolerance | 27.01 | 25.19 | 7 | 14285 | 264112 | 79465984 |
| Neurotoxicity | 26.66 | 25.19 | 31 | 14261 | 32487 | 79697609 |
| Pulmonary venous thrombosis | 26.17 | 25.19 | 6 | 14286 | 152 | 79729944 |
| Acral peeling skin syndrome | 26.07 | 25.19 | 5 | 14287 | 51 | 79730045 |
| Fixed eruption | 25.99 | 25.19 | 12 | 14280 | 2942 | 79727154 |
| Dermatitis bullous | 25.82 | 25.19 | 21 | 14271 | 14224 | 79715872 |
| Enterocolitis | 25.48 | 25.19 | 21 | 14271 | 14491 | 79715605 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | V03AF04 | VARIOUS ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS Detoxifying agents for antineoplastic treatment |
| ATC | V03AF10 | VARIOUS ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS Detoxifying agents for antineoplastic treatment |
| FDA CS | M0008658 | Folic Acid |
| FDA EPC | N0000178369 | Folate Analog |
| CHEBI has role | CHEBI:25212 | metabolites |
| CHEBI has role | CHEBI:35610 | antineoplastic agents |
| MeSH PA | D000931 | Antidotes |
| MeSH PA | D020011 | Protective Agents |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Megaloblastic anemia | indication | 53165003 | DOID:13382 |
| Folic acid deficiency | indication | 190633005 | |
| Malignant tumor of stomach | indication | 363349007 | DOID:10534 |
| Small intestine cancer | indication | 363509000 | DOID:10154 |
| Methotrexate Toxicity | indication | ||
| Adjunct to Fluorouracil Treatment of Colorectal Cancer | indication | ||
| Pyrimethamine Toxicity | indication | ||
| Trimethoprim Toxicity | indication | ||
| Sulfadiazine Toxicity | indication | ||
| Trimetrexate Toxicity | indication | ||
| Bone Marrow Suppression due to Folic Acid Antagonism | indication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 3.61 | acidic |
| pKa2 | 5.29 | acidic |
| pKa3 | 10.26 | acidic |
| pKa4 | 12.96 | acidic |
| pKa5 | 4.59 | Basic |
| pKa6 | 2.23 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| 4028507 | VUID |
| N0000182085 | NUI |
| 419573-16-3 | SECONDARY_CAS_RN |
| 68538-85-2 | SECONDARY_CAS_RN |
| 4028507 | VANDF |
| 4028508 | VANDF |
| CHEBI:63606 | CHEBI |
| CHEMBL1908841 | ChEMBL_ID |
| CHEMBL1908361 | ChEMBL_ID |
| DB11596 | DRUGBANK_ID |
| 1648126 | RXNORM |
| 132962 | MMSL |
| 21723 | MMSL |
| 25218 | MMSL |
| 35726 | MMSL |
| d05842 | MMSL |
| 005532 | NDDF |
| 005533 | NDDF |
| 395769006 | SNOMEDCT_US |
| 429990006 | SNOMEDCT_US |
| 433468002 | SNOMEDCT_US |
| 782479008 | SNOMEDCT_US |
| C2721771 | UMLSCUI |
| D058766 | MESH_DESCRIPTOR_UI |
| FOZ | PDB_CHEM_ID |
| CHEMBL3707343 | ChEMBL_ID |
| 135398559 | PUBCHEM_CID |
| 6883 | INN_ID |
| WA16A5Y52X | UNII |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Levoleucovorin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9558 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 23 sections |
| Levoleucovorin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-3201 | INJECTION, SOLUTION | 175 mg | INTRAVENOUS | ANDA | 23 sections |
| LEVOLEUCOVORIN CALCIUM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 14335-340 | INJECTION, SOLUTION | 10 mg | INTRAVENOUS | ANDA | 24 sections |
| LEVOLEUCOVORIN CALCIUM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 14335-341 | INJECTION, SOLUTION | 10 mg | INTRAVENOUS | ANDA | 24 sections |
| LEVOLEUCOVORIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-890 | INJECTION, SOLUTION | 175 mg | INTRAVENOUS | ANDA | 25 sections |
| LEVOLEUCOVORIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-915 | INJECTION, SOLUTION | 250 mg | INTRAVENOUS | ANDA | 25 sections |
| LEVOLEUCOVORIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-771 | INJECTION, SOLUTION | 175 mg | INTRAVENOUS | ANDA | 25 sections |
| LEVOLEUCOVORIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-773 | INJECTION, SOLUTION | 250 mg | INTRAVENOUS | ANDA | 25 sections |
| Biopar delta-FORTE | HUMAN PRESCRIPTION DRUG LABEL | 6 | 64661-793 | CAPSULE | 2.50 mg | ORAL | unapproved drug other | 11 sections |
| Biopar delta-FORTE | HUMAN PRESCRIPTION DRUG LABEL | 6 | 64661-793 | CAPSULE | 2.50 mg | ORAL | unapproved drug other | 11 sections |
| Biopar delta-FORTE | HUMAN PRESCRIPTION DRUG LABEL | 6 | 64661-793 | CAPSULE | 2.50 mg | ORAL | unapproved drug other | 11 sections |
| levoleucovorin | Human Prescription Drug Label | 1 | 68083-278 | INJECTION | 10 mg | INTRAVENOUS | ANDA | 23 sections |
| levoleucovorin | Human Prescription Drug Label | 1 | 68083-279 | INJECTION | 10 mg | INTRAVENOUS | ANDA | 23 sections |
| Levoleucovorin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70121-1099 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 23 sections |
| Levoleucovorin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70121-1099 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 23 sections |
| Levoleucovorin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70121-1099 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 23 sections |
| Levoleucovorin Calcium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70121-1572 | INJECTION, SOLUTION | 10 mg | INTRAVENOUS | ANDA | 23 sections |
| Levoleucovorin Calcium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70121-1572 | INJECTION, SOLUTION | 10 mg | INTRAVENOUS | ANDA | 23 sections |
| Levoleucovorin Calcium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70121-1572 | INJECTION, SOLUTION | 10 mg | INTRAVENOUS | ANDA | 23 sections |
| LEVOLEUCOVORIN CALCIUM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70436-209 | INJECTION, SOLUTION | 10 mg | INTRAVENOUS | ANDA | 23 sections |
| LEVOLEUCOVORIN CALCIUM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70436-210 | INJECTION, SOLUTION | 10 mg | INTRAVENOUS | ANDA | 23 sections |
| Levoleucovorin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71288-104 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 24 sections |
| Levoleucovorin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71288-104 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 24 sections |
| Levoleucovorin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71288-105 | INJECTION, SOLUTION | 10 mg | INTRAVENOUS | ANDA | 24 sections |
| Levoleucovorin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72266-120 | INJECTION | 10 mg | INTRAVENOUS | ANDA | 25 sections |
| Levoleucovorin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72266-120 | INJECTION | 10 mg | INTRAVENOUS | ANDA | 25 sections |
| Levoleucovorin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72266-121 | INJECTION | 10 mg | INTRAVENOUS | ANDA | 25 sections |
| Levoleucovorin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72266-121 | INJECTION | 10 mg | INTRAVENOUS | ANDA | 25 sections |
| Fusilev | Human Prescription Drug Label | 1 | 72893-009 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | NDA | 23 sections |
| Fusilev | Human Prescription Drug Label | 1 | 72893-009 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | NDA | 23 sections |